July 29, 2020 -- PathogenDx has been awarded a grant from the U.S. National Institutes of Health (NIH) to support expansion of its DetectX-Rv COVID-19 microarray assay to a national level.
The grant was provided under the NIH's Rapid Acceleration of Diagnostics (RADx) program for DetectX-Rv, a multiplex viral diagnostic assay that detects COVID-19, as well as COVID-like viruses and subsequent mutations from SARS-CoV-2, according to the firm. The multiplex system will enable thousands of samples to be tested each day, PathogenDx said.
The test is under consideration for an emergency use authorization from the U.S. Food and Drug Administration, according to the company.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current